MCID: CHL028
MIFTS: 56

Childhood Type Dermatomyositis

Categories: Rare diseases, Neuronal diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Skin diseases, Muscle diseases

Aliases & Classifications for Childhood Type Dermatomyositis

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 38 12 15
Juvenile Dermatomyositis 12 76 53 59 73
Dermatomyositis, Childhood Type 73
Childhood Dermatomyositis 12
Juvenile Myositis 53
Juvenile Dm 59
Jdm 53
Jpm 53

Characteristics:

Orphanet epidemiological data:

59
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:



Summaries for Childhood Type Dermatomyositis

NIH Rare Diseases : 53 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis. It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema, muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures. Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected.  About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue. Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements.

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to autoimmune disease of gastrointestinal tract and myositis. An important gene associated with Childhood Type Dermatomyositis is IFIH1 (Interferon Induced With Helicase C Domain 1). The drugs Abatacept and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and heart, and related phenotypes are dry skin and skin rash

Wikipedia : 76 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Related Diseases for Childhood Type Dermatomyositis

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 autoimmune disease of gastrointestinal tract 10.1 HLA-DQA1 TNFRSF25
2 myositis 10.1
3 type 1 diabetes mellitus 17 9.9 TNFRSF25 VWF
4 diabetes mellitus, insulin-dependent 9.9 HLA-DQA1 IFIH1 TNFRSF25
5 dermatomyositis 9.8
6 fibrodysplasia ossificans progressiva 9.6
7 calcinosis 9.6
8 collagen disease 9.5 EXOSC10 VWF
9 immune system disease 9.4 TNFRSF25 VWF

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis

Symptoms & Phenotypes for Childhood Type Dermatomyositis

Human phenotypes related to Childhood Type Dermatomyositis:

59 32 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dry skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0000958
2 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
3 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
4 cutaneous photosensitivity 59 32 frequent (33%) Frequent (79-30%) HP:0000992
5 poikiloderma 59 32 frequent (33%) Frequent (79-30%) HP:0001029
6 muscular hypotonia 59 32 frequent (33%) Frequent (79-30%) HP:0001252
7 dysarthria 59 32 occasional (7.5%) Occasional (29-5%) HP:0001260
8 muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0001324
9 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
10 limitation of joint mobility 59 32 occasional (7.5%) Occasional (29-5%) HP:0001376
11 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
12 hoarse voice 59 32 occasional (7.5%) Occasional (29-5%) HP:0001609
13 dysphonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001618
14 cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001638
15 angina pectoris 59 32 occasional (7.5%) Occasional (29-5%) HP:0001681
16 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
17 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
18 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
19 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
20 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
21 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
22 restrictive ventilatory defect 59 32 frequent (33%) Frequent (79-30%) HP:0002091
23 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
24 pulmonary fibrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002206
25 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
26 vasculitis 59 32 frequent (33%) Frequent (79-30%) HP:0002633
27 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
28 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
29 elevated serum creatine phosphokinase 59 32 hallmark (90%) Very frequent (99-80%) HP:0003236
30 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
31 muscle cramps 59 32 frequent (33%) Frequent (79-30%) HP:0003394
32 emg abnormality 59 32 occasional (7.5%) Occasional (29-5%) HP:0003457
33 elevated erythrocyte sedimentation rate 59 32 hallmark (90%) Very frequent (99-80%) HP:0003565
34 calcinosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0003761
35 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
36 elevated c-reactive protein level 59 32 hallmark (90%) Very frequent (99-80%) HP:0011227
37 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
38 bundle branch block 59 32 occasional (7.5%) Occasional (29-5%) HP:0011710
39 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
40 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
41 palpebral edema 59 32 hallmark (90%) Very frequent (99-80%) HP:0100540
42 mucosal telangiectasiae 59 32 hallmark (90%) Very frequent (99-80%) HP:0100579
43 telangiectasia of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0100585
44 myositis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100614
45 skin ulcer 59 32 frequent (33%) Frequent (79-30%) HP:0200042

GenomeRNAi Phenotypes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased HIV-1 infection GR00226-A 8.8 EXOSC10 SNRPC VWF

Drugs & Therapeutics for Childhood Type Dermatomyositis

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3 332348-12-6 10237
2 Antirheumatic Agents Phase 4,Phase 3,Phase 2
3 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
4 Hormone Antagonists Phase 4,Phase 3,Phase 2
5 Hormones Phase 4,Phase 3,Phase 2
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
7 Vaccines Phase 4
8 Adrenocorticotropic Hormone Phase 4
9 beta-endorphin Phase 4
10 Melanocyte-Stimulating Hormones Phase 4
11
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
12
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
13
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
14
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
15
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
16
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
17
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
18
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
21 Antiemetics Phase 3,Phase 2
22 Antifungal Agents Phase 3
23 Anti-Infective Agents Phase 3,Phase 2
24 Anti-Inflammatory Agents Phase 3,Phase 2
25 Antimetabolites Phase 3,Phase 2
26 Antimetabolites, Antineoplastic Phase 3,Phase 2
27 Antineoplastic Agents, Hormonal Phase 3,Phase 2
28 Autonomic Agents Phase 3,Phase 2
29 Calcineurin Inhibitors Phase 3
30 Cyclosporins Phase 3
31 Dermatologic Agents Phase 3,Phase 2
32 Folic Acid Antagonists Phase 3,Phase 2
33 Gastrointestinal Agents Phase 3,Phase 2
34 glucocorticoids Phase 3,Phase 2
35 Methylprednisolone acetate Phase 3,Phase 2
36 Methylprednisolone Hemisuccinate Phase 3,Phase 2
37 Neuroprotective Agents Phase 3,Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
39 Peripheral Nervous System Agents Phase 3,Phase 2
40 Prednisolone acetate Phase 3,Phase 2
41 Prednisolone hemisuccinate Phase 3,Phase 2
42 Prednisolone phosphate Phase 3,Phase 2
43 Protective Agents Phase 3,Phase 2
44 Vitamin B Complex Phase 3,Phase 2
45 Bone Density Conservation Agents Phase 2, Phase 3
46 Analgesics Phase 2, Phase 3
47 Analgesics, Non-Narcotic Phase 2, Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
49 Folate Nutraceutical Phase 3,Phase 2
50 Vitamin B9 Nutraceutical Phase 3,Phase 2

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
2 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
5 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
6 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
7 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
8 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
9 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
10 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
11 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
12 Creatine Supplementation in Pediatric Rheumatology Unknown status NCT01217320 Not Applicable
13 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005 Not Applicable
14 Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome Completed NCT00001973
15 The CARRA Registry Completed NCT01697254
16 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
17 Juvenile Dermatomyositis Recruiting NCT03433638
18 Incidence and Prevalence of Juvenile Dermatomyositis Recruiting NCT03432455
19 Adult and Juvenile Myositis Recruiting NCT00017914
20 Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases) Recruiting NCT00059748
21 Environmental Risk Factors for the Anti-synthetase Syndrome Recruiting NCT01276470
22 Yellow Fever Vaccine in Patients With Rheumatic Diseases Recruiting NCT03430388 Not Applicable
23 Study of Families With Twins or Siblings Discordant for Rheumatic Disorders Recruiting NCT00055055
24 Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes Available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Genetic Tests for Childhood Type Dermatomyositis

Anatomical Context for Childhood Type Dermatomyositis

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

41
Skeletal Muscle, Skin, Heart, Bone, Lung, Endothelial, T Cells

Publications for Childhood Type Dermatomyositis

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 234)
# Title Authors Year
1
Extensive skin ulcers in a child with juvenile dermatomyositis. ( 29367373 )
2018
2
Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists. ( 29925381 )
2018
3
Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. ( 29940960 )
2018
4
The Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium- to Long-standing Juvenile Dermatomyositis. ( 29953739 )
2018
5
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. ( 29361142 )
2018
6
Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. ( 29342499 )
2018
7
A Viral Polymyositis Masquerade: Life-Threatening Case of Juvenile Dermatomyositis Complicated by Systemic Capillary Leak Syndrome. ( 29720802 )
2018
8
Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. ( 29373707 )
2018
9
Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis. ( 29901756 )
2018
10
Recurrence of juvenile dermatomyositis 8A years after remission. ( 28050594 )
2017
11
Juvenile dermatomyositis positive for anti-DNA mismatch repair enzyme antibodies. ( 28073708 )
2017
12
Juvenile dermatomyositis: a tertiary center experience. ( 28058540 )
2017
13
A case of lipoatrophic diabetes induced by juvenile dermatomyositis. ( 28895299 )
2017
14
Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis. ( 28957546 )
2017
15
Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study. ( 28514969 )
2017
16
Myogenic progenitor cells exhibit IFN type I-driven pro-angiogenic properties and molecular signature during juvenile dermatomyositis. ( 28941175 )
2017
17
Juvenile dermatomyositis/polymyositis and lymphoma. ( 28477693 )
2017
18
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. ( 28977549 )
2017
19
Retinal Manifestations of Juvenile Dermatomyositis: Case Report of Bilateral Diffuse Chorioretinopathy with Paracentral Acute Middle Maculopathy and Review of the Literature. ( 28448730 )
2017
20
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. ( 28077146 )
2017
21
Race and income affects outcomes in juvenile dermatomyositis. ( 28434566 )
2017
22
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). ( 28934971 )
2017
23
Focal hyperkeratosis overlying the palmar faces of interphalangeal and metacarpophalangeal joints revealing a juvenile dermatomyositis. ( 28895209 )
2017
24
Juvenile Dermatomyositis: Key Roles of Muscle Magnetic Resonance Imaging and Early Aggressive Treatment. ( 28911766 )
2017
25
Panniculitis in juvenile dermatomyositis: Report of a case and review of the published work. ( 26971888 )
2016
26
Improvement of nailfold capillary microangiopathy after immunosuppressant therapy in a child with clinically amyopathic juvenile dermatomyositis. ( 27157691 )
2016
27
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. ( 27007612 )
2016
28
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. ( 27606477 )
2016
29
Calcinosis in juvenile dermatomyositis mimicking cold abscess. ( 27586213 )
2016
30
Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis. ( 27588444 )
2016
31
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. ( 27155307 )
2016
32
MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis. ( 26628598 )
2016
33
Muscle biopsy in combination with myositis-specific autoantibodies aids prediction of outcomes in juvenile dermatomyositis. ( 27214289 )
2016
34
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. ( 27623619 )
2016
35
Juvenile dermatomyositis: new clinical trial evidence to underpin therapeutic shared decision making. ( 27650736 )
2016
36
Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis. ( 26472413 )
2015
37
Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. ( 26493816 )
2015
38
In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset. ( 26500284 )
2015
39
Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels. ( 26581448 )
2015
40
A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma. ( 26489640 )
2015
41
Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study. ( 26493320 )
2015
42
Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis. ( 25800510 )
2015
43
Recovery of Severe Muscular and Fascial Calcinosis After Treatment With Bisphosphonates in a Child With Juvenile Dermatomyositis. ( 26203832 )
2015
44
Efficacy and safety of creatine supplementation in juvenile dermatomyositis: A randomized double-blind placebo-controlled cross-over trial. ( 25899989 )
2015
45
Radiographic patterns of soft tissue calcinosis in juvenile dermatomyositis and its clinical implications. ( 25654011 )
2014
46
The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. ( 25366934 )
2014
47
Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage. ( 24647150 )
2014
48
Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. ( 25288783 )
2014
49
Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. ( 24397895 )
2014
50
Unrecognized juvenile dermatomyositis complicated by calcinosis universalis: a case report from Cameroon. ( 24401174 )
2014

Variations for Childhood Type Dermatomyositis

Expression for Childhood Type Dermatomyositis

LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin-like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript (non-protein coding) Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1, interferon-inducible Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Skeletal Muscle + 4.61 0.000
7 IFI44L interferon-induced protein 44-like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin-like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon-induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon, alpha-inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 chemokine (C-X-C motif) ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4, Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin, heavy chain 3, skeletal muscle, embryonic Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM domain and HD domain 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon, alpha-inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly (ADP-ribose) polymerase family, member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon, gamma-inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1, 91kDa Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex 3 like, E3 ubiquitin ligase Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly (ADP-ribose) polymerase family, member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin, osteoblast specific factor Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.

Pathways for Childhood Type Dermatomyositis

GO Terms for Childhood Type Dermatomyositis

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein sumoylation GO:0016925 8.62 IFIH1 SAE1

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 single-stranded RNA binding GO:0003727 8.62 IFIH1 SNRPC

Sources for Childhood Type Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....